We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
-5.01%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$7.85B
AUM Growth
-$933M
Cap. Flow
-$365M
Cap. Flow %
-4.65%
Top 10 Hldgs %
37.02%
Holding
151
New
11
Increased
33
Reduced
26
Closed
20

Top Buys

Rank Stock Value
1
ELV icon
Elevance Health
ELV
+$137M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$91.8M
3
AET
Aetna Inc
AET
+$82.5M
4
HUM icon
Humana
HUM
+$78.7M
5
MRK icon
Merck
MRK
+$68M

Top Sells

Rank Stock Value
1
WCG
Wellcare Health Plans, Inc.
WCG
+$146M
2
MOH icon
Molina Healthcare
MOH
+$117M
3
ESRX
Express Scripts Holding Company
ESRX
+$102M
4
IPXL
Impax Laboratories, Inc.
IPXL
+$89.8M
5
ABBV icon
AbbVie
ABBV
+$79.7M

Sector Composition

Rank Sector Weight
1 Healthcare 94.02%
2 Financials 1.52%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALXN
1
DELISTED
Alexion Pharmaceuticals
ALXN
$415M 5.28%
3,388,386
+750,375
+28% +$91.8M
BIIB icon
2
Biogen
BIIB
$32.1B
$363M 4.63%
1,281,200
-52,700
-4% -$15.6M
CELG
3
DELISTED
Celgene Corp
CELG
$360M 4.58%
3,106,777
+158,200
+5% +$17.6M
BSX icon
4
Boston Scientific
BSX
$68.9B
$357M 4.55%
16,506,900
-704,800
-4% -$15.4M
AMGN icon
5
Amgen
AMGN
$212B
$341M 4.34%
2,331,800
-104,900
-4% -$15.8M
MRK icon
6
Merck
MRK
$325B
$272M 3.46%
4,836,730
+1,161,604
+32% +$68M
INCY icon
7
Incyte
INCY
$25.3B
$209M 2.66%
2,082,800
+232,622
+13% +$22.7M
SHPG
8
DELISTED
Shire pic
SHPG
$205M 2.61%
1,203,351
+140,000
+13% +$24.8M
LLY icon
9
Eli Lilly
LLY
$1.09T
$201M 2.57%
2,739,000
+698,500
+34% +$52M
ABBV icon
10
AbbVie
ABBV
$471B
$183M 2.33%
2,925,000
-1,304,900
-31% -$79.7M
WMGI
11
DELISTED
Wright Medical Group Inc
WMGI
$174M 2.22%
7,584,334
+228,101
+3% +$5.3M
HUM icon
12
Humana
HUM
$43.9B
$171M 2.17%
836,400
+412,900
+97% +$78.7M
PFE icon
13
Pfizer
PFE
$144B
$168M 2.14%
5,446,967
+1,724,028
+46% +$52.6M
A icon
14
Agilent Technologies
A
$39.6B
$165M 2.11%
3,629,900
-84,900
-2% -$3.85M
AGN
15
DELISTED
Allergan plc
AGN
$162M 2.06%
769,690
-9,000
-1% -$1.86M
VRTX icon
16
Vertex Pharmaceuticals
VRTX
$124B
$159M 2.03%
2,159,400
+547,400
+34% +$44.5M
HCA icon
17
HCA Healthcare
HCA
$90.7B
$148M 1.89%
2,002,200
+690,000
+53% +$51.7M
ELV icon
18
Elevance Health
ELV
$82.8B
$147M 1.87%
+1,021,600
New +$137M
ARRY
19
DELISTED
Array Biopharma Inc
ARRY
$141M 1.8%
16,088,800
+1,908,900
+13% +$14M
REGN icon
20
Regeneron Pharmaceuticals
REGN
$73.1B
$130M 1.66%
355,300
– –
EW icon
21
Edwards Lifesciences
EW
$49.1B
$127M 1.61%
4,054,200
-65,400
-2% -$2.12M
ICPT
22
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$122M 1.55%
1,120,000
– –
TMO icon
23
Thermo Fisher Scientific
TMO
$215B
$113M 1.44%
799,500
-17,000
-2% -$2.51M
SGYP
24
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$111M 1.42%
18,241,398
+12,264,750
+205% +$64.1M
IRWD icon
25
Ironwood Pharmaceuticals
IRWD
$602M
$111M 1.41%
8,646,112
-3,232,994
-27% -$40.8M
1
2 3 4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q4 2016 Portfolio in Review

As of Q4 2016, OrbiMed held 151 positions worth $7.85B, down 11% from $8.78B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

OrbiMed withdrew a net $365M in Q4 2016, closing 20 positions and reducing 26 holdings. Its most notable exit was Wellcare Health Plans, Inc., an estimated $146M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 93% a quarter earlier, followed by Financials.

Against the trend, OrbiMed opened a new position in Elevance Health worth $147M.

  • OrbiMed's largest Q4 2016 buy was Elevance Health: 1,021,600 shares worth $147M.
  • OrbiMed added most to Alexion Pharmaceuticals in Q4 2016, an estimated $91.8M increase.
  • OrbiMed's biggest Q4 2016 reduction was Molina Healthcare, cutting an estimated $117M.
  • OrbiMed fully exited Wellcare Health Plans, Inc. in Q4 2016, selling an estimated $146M.
  • OrbiMed's ten largest holdings make up 37% of its $7.85B portfolio in Q4 2016.
  • OrbiMed opened 11 new positions and closed 20 in Q4 2016.
  • OrbiMed's portfolio value fell 11% quarter-over-quarter to $7.85B.

Based on OrbiMed's 13F filing for Q4 2016, filed 14 Feb 2017.